Filed on behalf of Patent Owner Genentech, Inc. by:

David L. Cavanaugh (Reg. No. 36,476)
Lauren V. Blakely (Reg. No. 70,247)
Robert J. Gunther, Jr. (*Pro Hac Vice)*
Lisa J. Pirozzolo (*Pro Hac Vice*)
Kevin S. Prussia (*Pro Hac Vice*)
Andrew J. Danford (*Pro Hac Vice*)
WILMER CUTLER PICKERING
HALE AND DORR LLP
1875 Pennsylvania Ave., NW
Washington, DC 20006

Adam R. Brausa (Reg No. 60,287)
Daralyn J. Durie (*Pro Hac Vice*)
DURIE TANGRI LLP
217 Leidesdorff Street
San Francisco, CA 94111

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER, INC. AND
SAMSUNG BIOEPIS CO., LTD.;
Petitioners,

v.

GENENTECH, INC.,
Patent Owner.

Case IPR2017-01489[1]
U.S. Patent No. 6,407,213

PATENT OWNER'S MOTION TO STRIKE PURSUANT TO PAPER NO. 57

[1] Case IPR2017-02140 has been joined with this proceeding.

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS

Page

I. PETITIONERS' EVOLVING INVALIDITY THEORY 1

II. PETITIONERS' NEW ARGUMENTS ARE FORECLOSED BY FEDERAL CIRCUIT PRECEDENT, STATUTE, AND THE BOARD'S REGULATIONS 3

A. Applicable Law 3

B. Petitioners' Reliance on Foote 1989 is Improper 4

1. Petitioners' arguments and testimony regarding Foote 1989 present a new theory of unpatentability 4

2. The prejudice to Patent Owner outweighs any marginal relevance of Foote 1989 to unexpected results 6

C. Petitioners' Arguments as to the Kurrle Reference Are Improper 9

III. CONCLUSION 10

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF AUTHORITIES

Page(s)

CASES

Apple Inc. v. e-Watch Inc.,
IPR2015-00412, Paper 50 (PTAB May 6, 2016) 3

Coherus Biosciences Inc. v. AbbVie Biotech. Ltd.,
IPR2016-00188, Paper 54 (PTAB Jun. 9, 2017) 5

Cox Comms., Inc. v. AT&T Intellectual Prop. II, L.P,
IPR2015-01187, Paper 59 (PTAB Nov. 15, 2016)..........6

In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation,
676 F.3d 1063 (Fed. Cir. 2012) 7

Dexcom, Inc. v. Waveform Techs, Inc.,
IPR2016-01679, Paper 53 (PTAB Feb. 28, 2018) 3

Intelligent-BioSystems, Inc. v. Illumina Cambridge, Ltd.,
821 F.3d 1359 (Fed. Cir. 2016) 4, 8

Mylan Pharm. Inc. v. UCB Pharma GmbH,
IPR2016-00517, Paper 37 (PTAB Jul. 19, 2017)..........9

Wasica Fin. GmbH v. Cont'l Auto. Sys., Inc.,
853 F.3d 1272 (Fed. Cir. 2017) 3, 5, 8, 10

FEDERAL STATUTES

35 U.S.C. § 312(a) 3

35 U.S.C. § 325(d) 9

REGULATIONS

37 C.F.R. § 42.23 (b) 3

Patent Trial Practice Guide, 77 Fed. Reg. 48,612, 48,620 (Aug. 14, 2012) 3

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

Pursuant to Paper No. 57, Patent Owner files this motion to strike new evidence and argument presented in Petitioners' Reply (Paper 53) pertaining to the alleged disclosure of a "consensus" sequence in the prior art. First, Petitioners argue that a new exhibit, Foote 1989 (Ex. 1693), teaches that a "consensus" sequence was used by Petitioners' expert to generate the humanized antibody in Riechmann 1988 (Ex. 1569). Neither Foote 1989 nor Riechmann 1988 were cited or discussed in the Petition. Second, Petitioners present a new argument that Kurrle (Ex. 1571) discloses a humanized antibody with a "consensus" sequence. For the reasons below, the Board should strike the following:

- Exhibit 1693 submitted with Petitioners' Reply and the associated arguments and testimony that rely on this exhibit, including the last paragraph beginning on page 27 of the Reply; Ex. 1702, ¶¶ 12, 41-43, 61, 79, 82, 119, 162, and 187; Ex. 1697, 176:25-178:23; Ex. 2039, 327:12-331:11.
- The first full paragraph of page 18 of the Reply and the testimony relying on Petitioners' new theory including: Ex. 1702, ¶¶7, 44, 104-106, 160-162; Ex. 1697, 258:3-263:21, 264:9-267:18, 267:24-268:12; Ex. 2039, 313:7-320:11.

I. PETITIONERS' EVOLVING INVALIDITY THEORY

Claims 4, 33, 62, 64, and 69 require the use of a "consensus" sequence. The '213 patent provides a specific definition of the claimed human "consensus" sequence, "which comprises the most frequently occurring amino acid residues at

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

each location in all human immunoglobulins of any particular subclass or subunit structure." (Ex 1001, 11:32-38; Paper 27 at 9-10.) The Petition argued that the "consensus" limitation was met by either by Queen 1990 (Ex. 1550)'s disclosure of "us[ing] a consensus framework from many human antibodies," or by Queen 1989 (Ex. 1534)'s teaching "moving towards a consensus framework region" in combination with Kabat 1987 (Ex. 1552) and/or the PDB database. (*See* Paper 1 at 40-45, 55-56.) Petitioners did not argue in the Petition that Foote 1989, Riechmann 1988, or Kurrle anticipate, render obvious, or otherwise disclose a "consensus" sequence as claimed in the '213 patent.

Consistent with the arguments in the Petition, Patent Owner's Response focused on showing that neither Queen 1990 nor Queen 1989 disclosed—or would lead to—the "consensus" sequence limitation of claims 4, 33, 62, 64, and 69. (Paper 42 at 51-55; *id.* at 55-56 (arguing Kabat 1987 cannot cure Queen 1989's deficiencies).) For the first time in their Reply, Petitioners pivot from relying on Queen 1990 and Queen 1989 with respect to the "consensus" sequence limitations, and now invite the Board to find those limitations in a new reference, Foote 1989, as well as in Kurrle.

DOCKET ALARM Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

WHAT WILL YOU BUILD? | sales@docketalarm.com | 1-866-77-FASTCASE

fastcase®
Smarter legal research.